Elevated WBC Count
Consider white blood cell (WBC) proliferation in patients with infections and other inflammatory states, such as autoimmune disorders.
An increase in neutrophils commonly occurs during a bacterial infection.
Lymphocytosis can be found in tuberculosis (TB), acute bowel infections, and infectious mononucleosis.
Monocyte count is usually increased along with an elevated lymphocyte count.
Eosinophils can become increased in patients with allergic disorders, asthma, certain parasitic, and dermatologic disorders.
Elevated WBC counts may also be detected in patients with a variety of different types of leukemia and lymphomas.
It is important to promptly recognize an elevated WBC count associated with a diagnosis of leukemia or lymphoma.
Commonly Encountered Situations
Non-neoplastic proliferations of WBCs most commonly involve an increase in neutrophils with bacterial infection.
Elevation in lymphocytes and monocytes in patients with autoimmune disease is also frequently encountered.
Suggested Additional Lab Testing
The most important test is the WBC count and differential.
Peripheral blood smear and bone marrow aspirate, with or without bone marrow biopsy, is informative in the diagnosis of certain WBC proliferative states.
Serum protein electrophoresis with further evaluation is indicated if a plasma cell dyscrasia is found.
An evaluation for infection, either bacterial or parasitic, is useful if there is an increase in eosinophils.
Tests for autoimmune diseases (e.g., systemic lupus erythematous [SLE], rheumatoid arthritis) may explain an elevated lymphocyte and monocyte cell count.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy